Selective inhibition of the duck hepatitis B virus by a new class of tetraazamacrocycles

Antimicrobial Agents and Chemotherapy

Volumn 41, Issue 11, 1997, Pages 2579-2581

  Hantz, Olivier ^a   Borel, Christelle ^a   Trabaud, Carole ^b   Zoulim, Fabien ^a   Dessolin, Jean ^b   Camplo, Michel ^b   Vlieghe, Patrick ^b   Bouygues, Martin ^b   Trepo, Christian ^a   Kraus, Jean Louis ^b  

^a INSERM   (France)

^b Inst Natl S de la Rech Med U322   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; TETRAAZAMACROCYCLE; UNCLASSIFIED DRUG; VIRUS DNA;

ANIMAL CELL; ARTICLE; CHRONIC ACTIVE HEPATITIS; CONTROLLED STUDY; HEPATITIS B VIRUS; LIVER CELL CULTURE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DNA INTERACTION; SOUTHERN BLOTTING; VIRUS HEPATITIS; VIRUS INHIBITION; VIRUS REPLICATION;

EID: 0030720325     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.41.11.2579     Document Type: Article

References (26)

1. Block, T. M., X. Y. Lu, F. M. Platt, G. R. Foster, W. H. Gerlich, B. S. Blumberg, and R. A. Dwek. 1994. Secretion of human hepatitis B virus is inhibited by the imino sugar N-butyldeoxynojirimycin. Proc. Natl. Acad. Sci. USA 91:2235-2239.
2. Bridger, G., R. Skerlj, D. Thornton, S. Padmanabhan, S. Martellucci, G. Henson, M. Abrams, N. Yamamoto, K. De Vreese, R. Pauwels, and E. De Clercq. 1995. Synthesis and structure-activity relationships of pheylenebis-(methylene) linked bis-tetraazamacrocycles that inhibit HIV replication. Effect of macrocyclic ring size and substituents on the aromatic linker. J. Med. Chem. 38:366-378.
3. Chisari, F. V., and C. Ferrari. 1995. Hepatitis B virus immunopathogenesis. Annu. Rev. Immunol. 13:29-60.
4. De Clercq, E., N. Yanamoto, R. Pauwels, J. Balzarini, M. Witvrouw, K. De Vreese, Z. Debyser, B. Rosenwirth, P. Peichl, R. Datema, D. Thornton, R. Skerlj, F. Gaul, S. Padmanabhan, G. Bridger, G. Henson, and M. Abrams. 1994. Highly potent and selective inhibition of human immunodeficiency virus by the bicyclam derivative JM3100. Antimicrob. Agents Chemother. 38:668-674.
5. De Vreese, K., V. Kofler-Mongold, C. Leutgeb, V. Weber, K. Vermeire, S. Schacht, J. Anné, E. De Clercq, R. Datema, and G. Werner. 1996. The molecular target of bicyclams, potent inhibitors of human immunodeficiency virus replication. J. Virol. 70:689-696.
6. Dienstag, J. L., R. P. Perrillo, E. R. Schiff, M. Bartholomew, C. Vicary, and M. Rubin. 1995. A preliminary trial of lamivudine for chronic hepatitis B infection. N. Engl. J. Med. 333:1657-1661.
7. Doong, S.-L., C.-H. Tsai, R. F. Schinazi, D. C. Liotta, and Y.-C. Cheng. 1991. Inhibition of the replication of hepatitis B virus in vitro by 2′, 3′-dideoxy-3′-thiacytidine and related analogues. Proc. Natl. Acad. Sci. USA 88:8495-8499.
8. Fautz, R., B. Hussein, and C. Hechenberger. 1991. Application of the neutral red assay (NR assay) to monolayer cultures of primary hepatocytes: rapid colorimetric viability determination for the unscheduled DNA synthesis test (UDS). Mutat. Res. 253:173-179.
9. Fourel, I., J. M. Cullen, J. Saputelli, C. E. Aldrich, P. Schaffer, D. R. Averett, J. Pugh, and W. S. Mason. 1994. Evidence that hepatocyte turnover is required for rapid clearance of duck hepatitis B virus during antiviral therapy of chronically infected ducks. J. Virol. 68:8321-8330.
10. Hantz, O., F. Turin, and C. Trepo. 1993. Therapy for hepatitis, with emphasis on the role of interferons. Curr. Opin. Infect. Dis. 6:778-783.
11. Hoofnagle, J. H., and A. M. DiBisceglie. 1997. Drug therapy: the treatment of chronic viral hepatitis. N. Engl. J. Med. 336:347-356.
12. Jilbert, A. R., T. T. Wu, J. M. England, P. M. Hall, N. Z. Carp, A. P. O'Connel, and W. S. Mason. 1992. Rapid resolution of duck hepatitis B virus infection occurs after massive hepatocellular involvement. J. Virol. 66:1377-1388.
13. Krüger, M., H. Tillman, and C. Trautwein. 1996. Famciclovir treatment of hepatitis B virus recurrence after liver transplantation. A pilot study. Liver Transplant. Surg. 2:253-262.
14. Lai, C. L., C. K. Ching, A. K. M. Tung, E. Li, J. Young, A. Hill, B. C. Y. Wong, J. Dent, and P. C. Wu. 1997. Lamivudine is effective in suppressing hepatitis B virus DNA in Chinese hepatitis B surface antigen carriers: a placebo-controlled trial. Hepatology 25:241-244.
15. Lambert, V., S. Chassot, A. Kay, C. Trepo, and L. Cova. 1991. In vivo neutralization of duck hepatitis B virus by antibodies specific to the N-terminal portion of pre-S protein. Virology 185:446-450.
16. Ling, R., D. Mutimer, N. Ahmed, E. H. Boxall, E. Elias, G. M. Dusheiko, and T. J. Harrison. 1996. Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine. Hepatology 24:711-713.
17. Moraleda, G., T. T. Wu, A. R. Jilbert, C. E. Aldrich, L. D. Condreay, S. H. Larsen, J. C. Tang, J. M. Colacino, and W. S. Mason. 1993. Inhibition of duck hepatitis-B virus replication by hypericin. Antivir. Res. 20:235-247.
18. Offensperger, W. B., S. Offensperger, E. Walter, H. E. Blum, and W. Gerok. 1993. Suramin prevents duck hepatitis B virus infection in vivo. Antimicrob. Agents Chemother. 37:1539-1542.
19. Petcu, D. J., C. E. Aldrich, L. Coates, J. M. Taylor, and W. S. Mason. 1988. Suramin inhibits in vitro infection by duck hepatitis B virus, Rous sarcoma virus and hepatitis delta virus. Virology 167:385-392.
20. Sato, H., W. Goto, J. Yamamura, M. Kurokawa, S. Kageyama, T. Takahara, A. Watanabe, and K. Shiraki. 1996. Therapeutic basis of glycyrrhizin on chronic hepatitis B. Antivir. Res. 30:171-177.
21. Summers, J., P. M. Smith, and A. L. Horwich. 1990. Hepadnavirus envelope proteins regulate covalently closed circular DNA amplification. J. Virol. 64:2819-2824.
22. Tipples, G. A., M. M. Ma, K. P. Fischer, V. G. Bain, N. M. Kneteman, and D. L. J. Tyrrell. 1996. Mutation in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivo. Hepatology 24:714-717.
23. Trabaud, C., J. Dessolin, P. Vlieghe, M. Bouygues, M. Camplo, J. C. Cherman, and J. L. Kraus. 1997. Modelisation synthesis and anti-HIV activity of N,N,N′,N″,N‴-pentakis tetraazamacrocycle salt derivatives. Bioorg. Med. Chem. Lett. 7:1353-1358.
24. Trepo, C., P. Jezek, G. Atkinson, and R. Boon. 1996. Efficacy of famciclovir in chronic hepatitis B: results of a dose finding study. Hepatology 24:188A. (Abstract 24.)
25. Turin, F., C. Borel, M. Benchaib, T. Kay, C. Jamard, C. Guguen-guillouzo, C. Trepo, and O. Hantz. 1996. n-Butyrate, a cell cycle blocker, inhibits early amplification of duck hepatitis B virus covalently closed circular DNA after in vitro infection of duck hepatocytes. J. Virol. 70:2691-2696.
26. Zoulim, F., E. Dannaoui, C. Borel, O. Hantz, T. S. Lin, S. H. Liu, C. Trepo, and Y. C. Cheng. 1996. 2′,3′-Dideoxy-β-L-5-fluorocytidine inhibits duck hepatitis B virus reverse transcription and suppresses viral DNA synthesis in hepatocytes, both in vitro and in vivo. Antimicrob. Agents Chemother. 40: 448-453.